01 Oct
2019
16:30 E.S.T.

Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates

Read more

06 Aug
2019
16:30 E.S.T.

Cellectis Reports Financial Results for Second Quarter and First Six Months 2019

Read more

08 Jul
2019
16:30 E.S.T.

Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way

Read more

26 Jun
2019
16:30 E.S.T.

Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019

Read more

07 May
2019
16:30 E.S.T.

Cellectis Reports Financial Results for First Quarter 2019

Read more

17 Apr
2019
16:30 E.S.T.

Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting

Read more

02 Apr
2019
16:30 E.S.T.

FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients

Read more

11 Mar
2019
16:10 E.S.T.

Cellectis Reports 4th Quarter and Full Year 2018 Financial Results

Read more

07 Mar
2019
16:30 E.S.T.

Cellectis Enters Lease Agreement to Build Manufacturing Facility,  Advancing Towards Commercialization of its UCART Portfolio

Read more

25 Feb
2019
17:00 E.S.T.

Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry

Read more